Trial reportJournal of consulting and clinical psychology2026
Investigating craving as an indicator of early response to buprenorphine treatment among adults with opioid use disorder.
Trial report in Journal of consulting and clinical psychology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Investigating craving as an indicator of early response to buprenorphine treatment among adults with opioid use disorder.Journal of consulting and clinical psychology · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveReduction of craving is a key mechanism of buprenorphine treatment for opioid use disorder but has not been examined as an indicator of early response versus nonresponse. We aimed to (a) identify cut points for craving in the first week of buprenorphine treatment that best predicted later sustained opioid use and (b) examine associations between early nonresponse based on craving and opioid-related, retention, and psychosocial outcomes.
methodData were from two buprenorphine trials (N = 562; M
resultsSustained opioid use was optimally predicted by craving ≥2 in Week 1 (sensitivity = 0.700; specificity = 0.513, positive predictive value = 0.398, negative predictive value = 0.788). Participants above this threshold had 2.53 times greater odds 95% CI = [1.69, 3.81] of sustained opioid use. Craving-based nonresponse was also associated with fewer opioid-free weeks and poorer end-of-treatment depression and quality of life outcomes.
conclusionsEven mild craving early in buprenorphine treatment may signal an increased risk of poor outcomes, thus identifying those who could benefit from monitoring and low-effort interventions to manage craving. However, future work is needed to optimize the prediction of poor buprenorphine outcomes, potentially using models integrating both craving and opioid use in the first weeks of treatment. (PsycInfo Database Record (c) 2026 APA, all rights reserved).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.